Injections should always be performed by a licensed medical professional in a sterile environment
Dillon et al., in a phase I clinical trial, evaluated a vaccine containing nine breast-cancer-associated peptides (MHC I restricted) from MAGE-A1, 3A3, and AA10 proteins, CEA, NY-ESO-1, and HER2/neu along with a TLR3 agonist, Poly-ICLC, and an adjuvant derived from tetanus toxin
Melittin exhibits antibacterial, anti-fungal, and antileishmanial properties due to this interaction (Berhe et al., 2024)
This late-phase response explains why allergy symptoms often persist long after allergen exposure ends and why chronic allergic conditions like eczema and asthma involve ongoing tissue damage